The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDDDD.L Share News (DDDD)

  • There is currently no data for DDDD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

DIRECTOR DEALINGS: Tesco chair invests GBP100,000; Dechra exec sells

Fri, 16th Apr 2021 15:17

(Alliance News) - The following is a round-up of share dealings by London-listed company directors and managers announced on Friday and not separately reported by Alliance News:

----------

Tesco PLC - Welwyn Garden City, England-based grocer - Chair John Allan buys 44,426 shares at GBP2.25, worth GBP100,000 on Wednesday. Non-Executive Director Steve Golsby buys 8,608 shares at GBP2.25, worth GBP19,393, on Thursday.

----------

Dechra Pharmaceuticals PLC - Cheshire-based veterinary products - Tony Griffin, managing director of Dechra Veterinary Products EU, sells 25,000 shares at GBP38.52, worth GBP962,950, on Friday. Dechra says Griffin's sale is to widen his investment portfolio for long-term financial planning purposes. He continues to hold 45,650 shares.

----------

OptiBiotix Health PLC - York, England-based developer of compounds to treat obesity, high cholesterol, diabetes and skincare - Non-Executive Director Stephen Hammond buys 25,000 shares at 51.8 pence, worth GBP12,950, on Thursday. The purchase is his only holding, having joined the board in February. Hammond is a UK member of Parliament.

----------

4D Pharma PLC - Leeds-based live biotherapeutic products - Chief Executive Officer Duncan Peyton and Chief Scientific Officer Alex Stevenson take part in company's USD25.0 million equity raise in March. Peyton and Stevenson each subscribe for 658,840 shares at GBP1.10, together worth GBP1.4 million. Peyton now has 9.5 million shares, a 5.3% stake, and Stevenson 9.4 million.

----------

Power Metal Resources PLC - metals exploration and development in Africa, US and Canada - Chief Executive Paul Johnson buys 500,000 shares at 2.39p each, GBP11,957 in total, on Thursday. Johnson had bought another 500,000 shares on Thursday that was already reported, for a GBP23,452 total investment. He now has 62.5 million shares, a 5.5% stake.

----------

Parsley Box Group PLC - Edinburgh-based ready-meal deliveries - Non-Executive Chair Chris van der Kuyl and wife Heather buy 26,165 shares at GBP1.86 to GBP2.03, worth about GBP50,000, on April 1 and April 12. Van der Kuyl now holds 2.3 million shares directly and 1.6 million indirectly via 4J Studios Ltd, for a 9.4% total stake. Parsley listed on AIM on March 31 at an initial public offering price of 200p.

----------

InnovaDerma PLC - London-based beauty, personal care and life science products firm - Non-Executive Director Mark Ward buys 171,242 shares at 40.7p, worth GBP69,695, on Thursday. Ward now has 2.3 million shares, a 13.5% stake. He also has agreed to subscribe to 1.4 million new shares as part of InnovaDerma's placing announced back in January. Finance Director Andrew Dunderdale buys 24,937 shares at 40.1p, also on Thursday.

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
8 Apr 2016 08:25

4D Pharma Buys Assets From Partner In Deal Worth Up To EUR6 Million (ALLISS)

Read more
31 Mar 2016 08:47

4d Pharma Annual Loss Widens On Higher Research Spending

Read more
26 Feb 2016 15:49

Good news, and some not-so-good news from 4D pharma

(ShareCast News) - 4D pharma brought some good news and some bad news to the market on Friday, over its trials of irritable bowel syndrome (IBS) treatment Blautix, and it paediatric Crohn's disease treatment Thetanix. The AIM-traded pharmaceutical company, with a focus on the development of live bio

Read more
26 Feb 2016 09:16

4D Pharma Quality Concerns Delay Thetanix Dosing, Recruits For Blautic

Read more
10 Feb 2016 15:12

4D Pharma expands research with Tuscana acquisition

(ShareCast News) - 4D Pharma expanded its research capabilities on Wednesday, acquiring university-based startup Tuscana Health Limited. The AIM traded pharmaceutical company, focused on the development of live biotherapeutics, said Tuscana - based at University College Cork - was founded to investi

Read more
10 Feb 2016 08:57

4D Pharma Acquires University Start-Up Company Tucana Health (ALLISS)

Read more
19 Jan 2016 07:51

4d Pharma Gets Good Early Results From Blautix Trials

Read more
8 Dec 2015 07:46

4d Pharma Raises GBP30.0 Million For Business Development (ALLISS)

Read more
26 Nov 2015 10:10

4D Pharma Finds Live Biotherapeutic For Breast, Lung Cancer Treatment

Read more
11 Nov 2015 11:15

4D Pharma Gets Approval For Phase 1 Study Of Crohn's Disease Drug

Read more
29 Sep 2015 12:08

4D Pharma Progresses Pipeline As It Swings To Loss In First Half

Read more
21 Aug 2015 06:49

4D Pharma Commences Dosing In Irritable Bowel Syndrome Clinical Trial

Read more
11 Aug 2015 14:15

FTSE 250 movers: Miners drag index down, Synthomer spikes higher

(ShareCast News) - The FTSE 250 index was by late on Tuesday afternoon giving up some of the gains made late the day before, as commodities-focused stocks were hit by China's devaluation and corporate news received mixed reviews. By 1540 BST the index was down 0.47% at 17,677.29 points, with Vedanta

Read more
7 Aug 2015 06:31

4D Pharma Agrees EUR4.8 Million Collaboration With APC Microbiome

Read more
16 Jun 2015 08:33

4D Pharma posts "exciting" development results from MicroRx

Pharmaceutical company 4D Pharma said it had made significant progress in its research efforts using its proprietary platform MicroRx. The Manchester-based outfit was able to identify candidates for the treatment of severe asthma, allergic asthma and rheumatoid arthritis. The group also identified

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.